Actor portrayal.
Study results
In the clinical study, 85 out of 207 people (41%) taking ZENBEXUS + daratumumab and hyaluronidase-fihj + dexamethasone (ZDd) were minimal residual disease (MRD) negative with a complete response or better, compared with 44 out of 213 people (21%) taking daratumumab and hyaluronidase-fihj + bortezomib + dexamethasone (DVd). This was after a median† follow-up time of 16 months.‡
*Compared with those taking DVd.
†Median is the middle number in a group of numbers arranged from lowest to highest.
‡The conditional approval of ZENBEXUS is based on MRD negativity (or no detectable cancer cells). There are ongoing studies to see how well ZENBEXUS works.
The clinical study included people whose multiple myeloma had come back after treatment (relapsed) or stopped responding to their last therapy (refractory). 207 people took ZENBEXUS + daratumumab and hyaluronidase-fihj + dexamethasone (or “ZDd”) and 213 people took daratumumab and hyaluronidase-fihj + bortezomib + dexamethasone (or “DVd”).
A closer look at MRD
Why measure MRD?
Minimal residual disease (MRD) is measured to see if a very small amount of myeloma can be found after achieving complete response or better with treatment (when all signs of cancer have disappeared).
What is MRD negativity?
If you are MRD negative, it means that out of every 100,000 cells doctors checked, not one was found to be myeloma. Even if you have a complete response (CR) and are MRD negative, it’s not the same as being cured. There is a chance myeloma can still come back.
Do I need to be tested for MRD?
MRD is typically only measured in clinical studies. Since MRD testing is not part of standard multiple myeloma care, your oncologist may not test for it.
Safety & side effects
Talking to your doctor
Actor portrayals.
